A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY - ND

• Register: EUCTR
• Last refreshed on: 12 June 2012
• Main ID: EUCTR2006-001347-66-IT
• Date of registration: 04/12/2006
• Prospective Registration: Yes
• Primary sponsor: PFIZER
• Public title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY - ND
• Scientific title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY - ND
• Date of first enrolment: 19/02/2007
• Target sample size: 120
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001347-66
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: yes Other specify the comparator: Switch da Alprazolam farmaco iniziale

Countries of recruitment

Czech Republic, Italy, Spain

Key inclusion & exclusion criteria

Inclusion criteria:
1.Written informed consent must be obtained from all subjects prior to study entry. At the screening visit the investigator will be responsible for obtaining witnessed if applicable , written informed consent and documenting this in the source documents. A copy of the signed and dated informed consent form should be provided to the subject. 2. Age range 18-65 years 3. Both men and women are eligible for the study. Women of childbearing potential or 2 years post-menopausal must be practicing an approved method of contraception e.g. IUD, oral contraceptive for a least one cycle, implant or double barrier method and have a negative serum 946;-HCG at screening. Women who are breastfeeding are excluded from study participation. Complete abstinence may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer monitor prior to any screening tests or procedures for the study. 4. A primary lifetime diagnosis of DSM-IV-TRTM 2000 GAD. GAD will be diagnosed with the MINI International Neuropsychiatric Interview M.I.N.I Version 5.0.0. The more detailed Module P GAD from the M.I.N.I. Plus Version 5.0.0 11 will be used to assess the GAD diagnosis specifically. Subjects can sub-threshold for current GAD diagnosis. 5. Stable use of a benzodiazepine. The subject must be currently taking a benzodiazepine as prescribed by a licensed physician for at least 8 weeks prior to the screening visit, and not more than 52 weeks prior to the screening visit. 6. Screening laboratory values must be within normal limits and within sponsor 146;s guidelines, or if abnormal, considered and documented as not clinically significant by the investigator. Liver function tests 2 times the upper limit or normal are considered significant
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1.Pregnant or lactating women 2. Hamilton Depression Rating Scale HAM-D - 17 Item total score / 15 3. History of non-response to alprazolam, other benzodiazepines, gabapentine or pregabalin given for the treatment of anxiety as indicated by a screening or baseline HAM-A score 18 4. A current DSM-IV-TMTM 2000 diagnosis of major depressive disorder, dysthymia, social phobia, post-traumatic stress disorder, body dysmorphic disorder or eating disorder at screening or with the past 6 months. 5. A current or past DSM-IV diagnosis of schizophrenia, psychotic disorder, bipolar affective disorder or obsessive-compulsive disorder. 6. Meet DSM-IV criteria for any substance dependence in the past 5 years or abuse in past 12 months excluding nicotine dependence. 7. Receiving psychotherapy e.g. cognitive therapy, cognitive-behavioral therapy, supportive therapy or others in which the specific focus of the therapy is generalized anxiety disorder GAD and its symptoms or another anxiety disorder. Subjects who are contemplating beginning a course of psychotherapy and/or behavioral therapy during the course of the study. A history of seizure disorder, except febrile seizures of childhood. 9. A history of neuropathic pain 10. A history of narrow angle glaucoma 11. Use of fluoxetine within 5 weeks prior to the screening visit. 12. Use of psychotropic including antiepileptic medication other than benzodiazepines within 2 weeks prior to the screening visit. 13. Positive urine drug screen at the screening visit for the following substances or classes of drugs amphetamines, barbiturates, ethanol, narcotics, non-benzodiazepine sedatives and hypnotics, cocaine, phencyclidine PCP , cannabinoids, or other illegal or illicit drugs. 14. Mental condition, including mental retardation, rendering the individual unable to understand the nature, scope, and possible consequences of the study and/or evidence of any uncooperative attitude. 15. Considered by the Investigator to be at risk for suicide or aggressive behavior. 16. Any serious or uncontrolled medical illness, in the opinion of the investigator, will render the subject unsuitable for the study. 17. Any significant, serious, unstable hematological, autoimmune, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disorder that in the opinion of the Investigator will render the subject unsuitable for the study. 18. Creatinine clearance / 60 ml/min estimated from serum creatinine, body weight, age and sex using the Cockroft-Gault equation.Subjects who have an estimated creatinine clearance of less than 60 ml/min by this screening method may, at the investigators discretion, have their creatinine clearance measured with a 24-hour urine collection, performed at the central laboratory. If this 24-hour urine creatinine clearance is greater than 60 ml/min, the subject may be eligible for the study. 19. Received or have received electroconvulsive therapy within six 6 months prior to study entry. 20. In the judgment of the investigator, the subject is unable to follow the protocol, or otherwise might not be suitable for the study. 21. Known sensitivity to pregabalin, other drugs structurally related to the neurotransmitter GABA, alprazolam or other benzodiazepines. 22. Participation in any other studies involving investigational or marketed products, concomitantly or within 3 months prior to study en

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Generalized Anxiety Disorder GAD
MedDRA version: 8.1 Level: LLT Classification code 10002855 Term: Anxiety

Intervention(s)

Product Name: Pregabalin
Product Code: PD 0144723 CI-1008
Pharmaceutical Form: Capsule, hard
CAS Number: 148553-50-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Product Name: Pregabalin
Product Code: PD 0144723 CI-1008
Pharmaceutical Form: Capsule, hard
CAS Number: 148553-50-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Product Name: Pregabalin
Product Code: PD 0144723 CI-1008
Pharmaceutical Form: Capsule, hard
CAS Number: 148553-50-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 225-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Product Name: Pregabalin
Product Code: PD 0144723 CI-1008
Pharmaceutical Form: Capsule, hard
CAS Number: 148553-50-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Pharmaceutical Form: Tablet
INN or Proposed INN: Alprazolam
CAS Number: 28981-97-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: .25-

Pharmaceutical Form: Tablet
INN or Proposed INN: Alprazolam
CAS Number: 28981-97-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: .5-

Pharmaceutical Form: Tablet
INN or Proposed INN: Alprazolam
CAS Number: 28981-97-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-

Primary Outcome(s)

Primary end point(s): The primary endpoint of this study is the proportion of subjects who are free of benzodiazepine and other psychoactive drugs during the six weeks of the Alprazolam-Free Phase of Double-Blind Treatment. Being free of benzodiazepine and/or other psychoactive drugs is defined as Negative urine benzodiazepine/psychoactive toxicology assay done at each visit of the Alprazolam-Free Phase of Double-Blind Treatment and negative serum benzodiazepine/alcohol assay done at endpoint

Secondary Objective: To obtain additional data on the efficacy of pregabalin in reducing the severity of symptoms of GAD, rebound anxiety, benzodiazepine withdrawal, and titration regimen in comparison to placebo after switching from a stable therapeutic dose of alprazolam to treatment with pregabalin or placebo.

Main Objective: To evaluate the efficacy of pregabalin in maintaining the benzodiazepine -free state in subjects with prior stable alprazolam use.

Secondary ID(s)

2006-001347-66-ES

A0081092